US Bancorp’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

US Bancorp’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,569	Closed	-$276K	–	4178
2023 Q1	$276K	Buy	2,569 +29	+1%	+$3.34K	﹤0.01%	1718
2022 Q4	$279K	Buy	2,540 +2,419	+1,999%	+$157K	﹤0.01%	1683
2022 Q3	$7K	Hold	121	–	–	﹤0.01%	3516
2022 Q2	$3K	Hold	121	–	–	﹤0.01%	3781
2022 Q1	$5K	Hold	121	–	–	﹤0.01%	3644
2021 Q4	$5K	Buy	+121	New	+$3.79K	﹤0.01%	3683

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

US Bancorp's RXDX Position: Q2 2023 in Review

US Bancorp sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 2,569 shares — an estimated $276K sold.

US Bancorp first reported a position in RXDX in Q4 2021 and held it in 6 quarters. The position peaked at $279K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

US Bancorp reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
US Bancorp sold 2,569 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $276K.
US Bancorp first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
US Bancorp's Prometheus Biosciences, Inc. Common Stock position peaked at $279K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on US Bancorp's 13F filing for Q2 2023, filed 10 Aug 2023.